

#### 4.0.03 DOC Working group minutes

### Epilepsies Working Group meeting

**Date:** 10/02/2024

**Location:** Virtual

**Minutes:** Confirmed

<b>Committee members present:</b>		
Elizabeth Kay (Chair)		Present for notes 1 – 3
Helen Cross (Topic adviser)		Present for notes 1 – 3
Arjune Sen (Topic adviser)		Present for notes 1 – 3
Rachel Batchelor		Present for notes 1 – 3
Christine Cole		Present for notes 1 – 3
Anita Devlin		Present for notes 1 – 3
Mo Eyeoyibo		Present for notes 1 – 3
Richard Grunewald		Present for notes 1 – 3
Philip Smith		Present for notes 1 – 3
Ashifa Trivedi		Present for notes 1 – 3

<b>In attendance:</b>		
Angela Bennett	Director of Guidelines, GDT-NGA	Present for notes 1 – 3
Eric Power	Programme Director	Present for notes 1 – 3
Louise Bate	Consultant Clinical Adviser	Present for notes 1 – 3
Catharine Baden-Daintree	Senior Medical Editor	Present for notes 1 – 3
Sarah Mee	Senior Medical Assessor, MHRA	Present for notes 1 – 3
Leigh Henderson	Head of Neuropsychiatric disorders, Cognition and Mental Health Safety and Surveillance, MHRA	Present for notes 1 – 3

#### 4.0.03 DOC Working group minutes

##### **1. Welcome and objectives for the meeting**

The Chair welcomed the members and attendees to the 2nd meeting of the Epilepsies Working Group.

The Chair informed the Working Group that no apologies had been received.

The Chair outlined the objectives of the meeting, which were to review the recommendations from NG217 about the use of sodium valproate and agree if changes were needed in light of changes made to the regulations by the MHRA.

##### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was use of sodium valproate for the treatment of epilepsies

A record of the interests declared by Working Group members is available on the NICE website. No new interests were declared at the meeting.

A senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

##### **3. Presentations and discussion**

The Working Group were presented with data received by the CHM on valproate and discussed its impact on the recommendations in the guideline.

Angela Bennett presented the effectiveness evidence included in NG217 for the recommendations about safety, monitoring and review and antiseizure medications for women and girls.

The Working Group then discussed the issues in relation to these recommendations.

**Date of next meeting:** To be confirmed

**Location of next meeting:** Virtual